Combination therapy with 2‐ME2 and EPZ6438 demonstrated promising antitumor activity in an in vivo A549 xenograft tumor model, suggesting that dual targeting of HIF‐1α and EZH2 is an emerging and attractive therapeutic approach. The gene discussed is HIF1A; the disease is neoplasm.